-
for adult patients with type 2 diabetes mellitus (metformin + dipeptidyl peptidase 4 inhibitor + SLG-2 inhibitor).
Time of Update: 2022-11-14
Guide name: Chinese expert consensus on the triple optimization scheme of oral hypoglycemic drugs (metformin + dipeptidyl peptidase 4 inhibitor + sodium⁃glucose cotransporter 2 inhibitor) for adult pa
-
Combination of dipeptidyl peptidase-4 inhibitor with two sulfonylureas contributes to normalization of islet beta cell number
Time of Update: 2022-09-06
Another group of commonly used antidiabetic drugs are dipeptidyl peptidase-4 inhibitors (DPP4i), these drugs tend to increase the replication of beta cells and inhibit their apoptosis, in addition, DPP4i can restore the response of alpha cells to glucagon levels physiological regulation .
-
JAMA Netw Open: Association of glucagon-like peptide-1 receptor agonist versus dipeptidyl peptidase
Time of Update: 2022-04-20
Analysis of primary and secondary outcomesConclusions: In patients with type 2 diabetes, advanced CKD, and ESKD, treatment with GLP-1 receptor agonists was associated with lower all-cause mortality than patients with DPP-4 inhibitors .
-
Diabetes Care: Safety comparison of sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase
Time of Update: 2022-04-17
Objective: To evaluate the association of sodium-glucose cotransporter 2 (SGLT2) inhibitors with diabetic ketoacidosis compared with dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas .
In Cox proportional hazards regression models, use of SGLT2 inhibitors was associated with a higher incidence of diabetic ketoacidosis compared with DPP-4 inhibitors (adjusted HR [aHR] 1.
-
Diabetes Obes Metab: The effect of dipeptidyl peptidase-4 inhibitor linagliptin and sulfonylurea
Time of Update: 2021-11-12
Results: Compared with glimepiride, linagliptin increased postprandial glomerular filtration fraction (FF; average difference of 2.
Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial .
-
Diabetes Obes Metab: Effects of dipeptidyl peptidase 4 inhibitors and sulfonylureas on the cognition and physical function of nursing home residents
Time of Update: 2021-11-01
Compared with sulfonylureas (SU), dipeptidyl peptidase 4 inhibitors (DPP4Is) can alleviate the decline in cognitive and physical function induced by hypoglycemia , but they are not available in the elderly, especially in nursing homes (NH) residents.
-
Neurology: Dipeptidyl peptidase-4 inhibitor may improve cognitive decline in patients with diabetic dementia
Time of Update: 2021-08-27
This study shows that the use of DPP-4i is associated with low amyloid burden and favorable long-term cognitive outcomes in ADCI diabetic patients .
The use of DPP-4i is associated with low amyloid burden and favorable long-term cognitive outcomes in ADCI diabetic patients .